Quarterly report · Q1
4544.TEDINET S100RLNC
Period2023-04-01 → 2023-06-30
Filed2023-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥56.6bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥260.9bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥65.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | −¥1.7bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥8.6bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | −¥1.5bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥22.0bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥8.5bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥1.2bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥8.1bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.1bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥15.7bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥5.6bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥1.1bn | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥5.6bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥289.6bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥297.9bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥278.3bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥139.8bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥147.9bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥149.8bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥150.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥146.0bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥32.7bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥44.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥32.7bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥44.2bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥39.7bn | at 2022-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥46.5bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥6.2bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥32.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥6.1bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥4.0bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥29.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥7.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.7bn | 2023-04-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.8bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥6.4bn | 2022-04-01 → 2022-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-19.67 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥275.52 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.25 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥275.5 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥98.24 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 51.7% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.4% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥1.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥1.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥1.6bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥36.1bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥36.1bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥18m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | −¥2.8bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥14.7bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥13.4bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1.4bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥2.3bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥7.2bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥7.2bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1m |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥355m |
| —segment total | revenue | 2023-04-01 → 2023-06-30 | ¥58.0bn |
| —segment total | revenue external | 2023-04-01 → 2023-06-30 | ¥56.6bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥1.4bn |
| —segment total | segment profit | 2023-04-01 → 2023-06-30 | −¥121m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥3.5bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥3.5bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥607m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥43.4bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥43.4bn |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥27m |
| jpcrp040300-q1r_E00967-000Clinical Lab Testing Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥1.7bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥18.5bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥15.0bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.5bn |
| jpcrp040300-q1r_E00967-000In Vitro Diagnostics Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥4m |
| jpcrp040300-q1r_E00967-000Sterilization And Related Servicesreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥440m |
| —segment total | revenue | 2022-04-01 → 2022-06-30 | ¥68.8bn |
| —segment total | revenue external | 2022-04-01 → 2022-06-30 | ¥65.3bn |
| —segment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.5bn |
| —segment total | segment profit | 2022-04-01 → 2022-06-30 | ¥9.2bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 459
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 261100 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 57093000 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 570930 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 117767 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 57471867 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 570930 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 261100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 261100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0045 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 261100 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 261100 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0045 | |
| Cash and deposits | Prior1YearInstant | 44186000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 32736000000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 46946000000 | JPY |
| Notes and accounts receivable trade and contract assets | CurrentQuarterInstant | 45120000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 6469000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 6549000000 | JPY |
| Work in process | Prior1YearInstant | 7072000000 | JPY |
| Work in process | CurrentQuarterInstant | 7920000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 8587000000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 9260000000 | JPY |
| Other ca | Prior1YearInstant | 19359000000 | JPY |
| Other ca | CurrentQuarterInstant | 20215000000 | JPY |
| Allowance for doubtful accounts ca | Prior1YearInstant | -770000000 | JPY |
| Allowance for doubtful accounts ca | CurrentQuarterInstant | -559000000 | JPY |
| Current assets | Prior1YearInstant | 131851000000 | JPY |
| Current assets | CurrentQuarterInstant | 121243000000 | JPY |
| Buildings and structures net | Prior1YearInstant | 24062000000 | JPY |
| Buildings and structures net | CurrentQuarterInstant | 26200000000 | JPY |
| Tools furniture and fixtures net | Prior1YearInstant | 21846000000 | JPY |
| Tools furniture and fixtures net | CurrentQuarterInstant | 21735000000 | JPY |
| Land | Prior1YearInstant | 10836000000 | JPY |
| Land | CurrentQuarterInstant | 10915000000 | JPY |
| Other net ppe | Prior1YearInstant | 23467000000 | JPY |
| Other net ppe | CurrentQuarterInstant | 21655000000 | JPY |
| Property plant and equipment | Prior1YearInstant | 80214000000 | JPY |
| Property plant and equipment | CurrentQuarterInstant | 80506000000 | JPY |
| Goodwill | Prior1YearInstant | 4453000000 | JPY |
| Goodwill | CurrentQuarterInstant | 4715000000 | JPY |
| Customer related intangible assets ia | Prior1YearInstant | 1956000000 | JPY |
| Customer related intangible assets ia | CurrentQuarterInstant | 2061000000 | JPY |
| Software | Prior1YearInstant | 22186000000 | JPY |
| Software | CurrentQuarterInstant | 21416000000 | JPY |
| Other ia | Prior1YearInstant | 16776000000 | JPY |
| Other ia | CurrentQuarterInstant | 17363000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |